Fast Five Quiz: Metastatic Melanoma Treatment

Winston W. Tan, MD, FACP


May 24, 2023

Patients who progressed after first-line targeted therapy and second-line immunotherapy can be rechallenged with targeted therapy, as strengthened antitumor immunity might contribute to the success of rechallenge after exposure to ICIs.

In the absence of strong evidence in metastatic melanoma, switching to immunotherapy in the absence of PD with targeted therapy should not be regularly considered outside of clinical trials.

Stopping treatment is common in clinical practice after 2 years of treatment with anti-PD-1 therapy when a patient achieves a PR or has stable disease. However, there are numerous considerations for stopping therapy in patients who respond to ICIs, including long-term side effects.

Learn more about advanced-stage melanoma management strategies.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.